IMRX vs. NBRV, AADI, XLO, GANX, OCUP, NXTC, ACXP, CLNN, DARE, and HCWB
Should you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), Xilio Therapeutics (XLO), Gain Therapeutics (GANX), Ocuphire Pharma (OCUP), NextCure (NXTC), Acurx Pharmaceuticals (ACXP), Clene (CLNN), Daré Bioscience (DARE), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical preparations" industry.
Immuneering (NASDAQ:IMRX) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment.
Immuneering has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Immuneering's return on equity of -55.79% beat Nabriva Therapeutics' return on equity.
In the previous week, Immuneering had 1 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 2 mentions for Immuneering and 1 mentions for Nabriva Therapeutics. Immuneering's average media sentiment score of 1.25 beat Nabriva Therapeutics' score of 0.00 indicating that Immuneering is being referred to more favorably in the media.
67.7% of Immuneering shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 25.0% of Immuneering shares are held by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Immuneering currently has a consensus price target of $13.50, indicating a potential upside of 844.06%.
Nabriva Therapeutics received 369 more outperform votes than Immuneering when rated by MarketBeat users. However, 61.54% of users gave Immuneering an outperform vote while only 58.14% of users gave Nabriva Therapeutics an outperform vote.
Immuneering has a beta of -0.6, indicating that its stock price is 160% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.
Immuneering has higher earnings, but lower revenue than Nabriva Therapeutics. Immuneering is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Immuneering beats Nabriva Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Immuneering News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immuneering Competitors List
Related Companies and Tools
